Pharmaxis appoints experienced industry executive to its board

Latest News

Pharmaxis (ASX:PXS) has announced the appointment of experienced senior global biopharmaceutical executive Dr Simon Green to its board as an independent non-executive director.

Dr Green has 30 years of experience in the biotechnology industry focused on the discovery, development and commercialisation of medicines.

He worked in the US at Genentech and Chiron before joining CSL in 1998.

Dr Greenheld roles as senior vice president of Global Plasma R&D and general manager of CSL’s manufacturing plants in Germany and Australia.

Pharmaxis chairman Malcolm McComas said, “We are delighted to welcome Simon to the Pharmaxis Board. He is an innovator with a strong drive to improve the lives of patients and his deep experience in product development at CSL is very relevant to our near-term plans for the commercialization of our drug candidates for myelofibrosis and other fibrotic diseases.”

Dr Green added, “I look forward to contributing to the pipeline of exciting new products at Pharmaxis. The company has an impressive team, excellent facilities and an exciting portfolio of commercially attractive product candidates for the treatment of diseases with serious unmet medical needs.”

Dr Green is also a non-executive director of Clover Corporation (ASX:CLV) and is the founder and CEO of the start-up diagnostics company Immunosis. He is also a venture partner and investment advisor at healthcare investment firm BioScience Managers and serves on the scientific advisory board for Imunexus.